Twelve deals above $100 million. Average deal sizes climbing to $36.7 million. AI capturing nearly half of all healthcare venture investment. In the first ninety days of 2026, the US digital health market absorbed more than $4 billion in capital, and the conditions driving that investment are structural, not cyclical. For European and Irish healthtech companies watching from outside the US market, the question has moved on from whether the market is open. The question now is whether your organisation is positioned to move before the window narrows. Understanding the threat landscape your US prospects are navigating is an asset in those conversations: our article on How Healthcare Cyber Security Threats have Professionalised provides context that resonates directly with US health system security teams.
This article sets out what is structurally changing in the US digital health landscape, what it means for European companies weighing their entry options, and what a credible go-to-market strategy needs to account for in 2026.
The capital flowing into US digital health in Q1 2026 is following a specific set of policy and regulatory changes that have materially altered the conditions for market entry and commercial scale.
In January 2026, the FDA eased oversight requirements on lower-risk AI-enabled clinical decision-support tools, allowing a significant category of digital health products to reach the US market without full device clearance. For European companies with CE-marked or MDR-compliant AI tools, this change removes one of the most cited barriers to US entry and creates a direct route to commercialisation for products that would previously have faced a far longer regulatory pathway.
The Centers for Medicare and Medicaid Services ACCESS Model, launching in July 2026, creates a direct reimbursement mechanism for technology-enabled chronic disease management. A credible reimbursement pathway for this product category simply did not exist two years ago. Its arrival changes the commercial calculus for any digital health company with a chronic condition management offering, transforming what was previously a pilot-dependent market into one with a fundable, scalable revenue model.
Physician adoption of AI tools in the US now sits at 63%, representing a 16-percentage point increase in nine months. That figure signals a market that has moved past the early-adopter phase. The infrastructure, the habits, and the institutional expectations are being locked in now. Companies entering the market in 2026 and 2027 will face a more established competitive field than those who moved twelve months earlier. Speed of entry and depth of clinical differentiation both matters more in this context than they did at the start of the adoption curve.
Alongside the investment surge, consolidation among large US digital health platforms is accelerating. Well-funded acquirers are actively seeking proven point solutions rather than building capability in-house. For European healthtech companies, this dynamic is a route to market as much as it is a competitive threat.
A deliberate partnership or acquisition conversation with the right US platform can deliver commercial scale that a standalone build in the US market would take three to five years to achieve independently. The platforms acquiring point solutions in Q1 2026 are building ecosystems, and they are looking for products with clinical evidence, regulatory rigour, and a differentiated position in their category.
European companies with CE marking, MDR compliance history, and GDPR-architected data governance carry a genuine advantage in these conversations. The regulatory discipline built under European frameworks is a credible differentiator in a US market that is learning, sometimes in difficult ways, what responsible AI deployment requires. That advantage has a defined shelf life as US competitors build their own evidence bases, but it is real and available now.
The consolidation landscape in most digital health categories can be mapped. Identifying the three to five US platforms most likely to acquire or deeply integrate a product in your category is not a speculative exercise. It is a structured commercial analysis that should precede any significant US investment, and the relationship-building that converts that analysis into a live conversation takes time and trust. Those conversations need to begin before you need them, not at the point when a deal timeline is pressing.
For European and Irish companies weighing their position in the US digital health market, three priorities deserve immediate attention.
In the US, a product's commercial viability is inseparable from its reimbursable. A go-to-market strategy that cannot map a credible pathway to CMS coverage or commercial insurance reimbursement is a pilot strategy, not a commercial strategy. Understanding whether your product category has a CPT code, an ICD pathway, or a value-based care alignment is foundational knowledge that should inform every investor and partner conversation, not something resolved after the first commercial setback.
The companies that struggle in the US market consistently identify the same root cause: not a weak product, but an underestimation of how different the operating environment is. Payer mix complexity, state-level regulatory variation, care setting heterogeneity, and the dynamics of US health system procurement all require specific expertise that cannot be improvised. Hiring reimbursement expertise, regulatory counsel, and US commercial leadership before you need them is consistently the right decision, and consistently the one that gets deferred too long.
Twelve to eighteen months is a reasonable planning horizon for building a meaningful US commercial presence. Companies that budget for six typically spend twelve and arrive at the market depleted. A Boston pilot is not a US strategy. Commercial models built for the US market need to account for payer mix variation, state regulatory differences, and care setting diversity from the outset, not as corrections applied after initial market contact.
At Santegic, we work with European and Irish healthtech companies to develop the go-to-market strategy, regulatory positioning, and commercial frameworks needed to enter the US digital health market with a credible, evidence-based approach rather than an optimistic one.
One of the most underused advantages available to European healthtech companies entering the US market is the regulatory history they have already built. CE marking, MDR compliance, and GDPR-architected data governance are not simply boxes ticked for European market access. In US commercial conversations with health systems, payers, and platform acquirers, they represent evidence of product rigour, clinical safety discipline, and data governance maturity that a significant proportion of US-native competitors cannot yet demonstrate.
That framing needs to be explicit. European companies that present their regulatory history as a compliance overhead rather than a commercial differentiator are leaving a meaningful competitive advantage unused at precisely the moment when the US market is most receptive to it.
The US digital health market in 2026 is not pausing for European companies to arrive on their own terms. The capital is moving, the consolidation is accelerating, and the clinical adoption window that makes this moment structurally different from previous cycles is open now. The companies that look back on this period as their entry point are already in motion.
For European and Irish healthtech companies ready to assess their US market position seriously, the work starts with reimbursement strategy, consolidation mapping, and a commercial model built for the heterogeneity of the US system, not the homogeneity of a single pilot site.
If your organisation needs support developing a credible digital health go-to-market strategy for the US market, Santegic's healthcare consulting services are available to help. Get in touch to discuss your market entry position and where specialist advisory can make the most difference.
Santegic delivers specialist go-to-market strategy, regulatory advisory, and commercial development support to European and Irish healthtech companies expanding into the US and global digital health markets.
One conversation. The right expertise.
